Chinese early-stage pharmaceutical firm Ractigen Therapeutics has announced the raising of 110 million yuan ($17 million) in its Series A round led by Asia-focused PE firm Hillhouse Capital’s venture unit GL Ventures, the investor announced on February 11.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
